(Total Views: 240)
Posted On: 08/25/2022 10:41:34 PM
Post# of 1418
"A spokesman for Pfizer declined to comment on the results, which were published in the New England Journal of Medicine."
Gerald did comment...
Gerald Commissiong@G_Commish 13h
"I mean it’s terrible news in general, especially for the US Gov’t that bought 20M courses of #Paxlovid. For #Tollovid users, I would bet a pep in their step today. And certainly the tools aren’t looking so hot right now"
Likely the aids drug messing it up. Gerald on the cc call said he didn't want to compete with Pfizer and would go after areas where they aren't in.
Well today, a whole giant area just opened up. 40 to 65 is a lot of people. With Paxlovid knocked out of the race, there is only one horse left. I think 3CL Valuation may have taken one giant leap.
Gerald did comment...
Gerald Commissiong@G_Commish 13h
"I mean it’s terrible news in general, especially for the US Gov’t that bought 20M courses of #Paxlovid. For #Tollovid users, I would bet a pep in their step today. And certainly the tools aren’t looking so hot right now"
Likely the aids drug messing it up. Gerald on the cc call said he didn't want to compete with Pfizer and would go after areas where they aren't in.
Well today, a whole giant area just opened up. 40 to 65 is a lot of people. With Paxlovid knocked out of the race, there is only one horse left. I think 3CL Valuation may have taken one giant leap.
(1)
(0)Scroll down for more posts ▼
